期刊文献+

海洋抗肿瘤候选药物普那布林(Plinabulin)及其类似物的研究进展 被引量:4

The progress of the development of marine antitumor drug Plinabulin and its analogues
原文传递
导出
摘要 微管蛋白是细胞骨架的重要组成部分,在维持形态、信号传导及有丝分裂等过程中起着重要的作用。普那布林(Plinabulin)是在从海洋焦曲霉菌中分离得到的天然产物Phenylahistin结构基础上,经构效关系研究,合成出的二酮哌嗪类微管蛋白抑制剂。普那布林作为抗肿瘤候选药物,目前已进入临床三期研究。近年来,为了获得高效、低毒和生物利用度更高的普那布林衍生物,本领域研究人员进行了大量的优化研究,获得了一些具有更好活性的衍生物。本文就普那布林及其类似物优化的研究进展进行综述。 Tubulin is one of the key components of cytoskeleton and plays an important role in the maintenance of cell shape and the process of signal transduction and mitosis.Plinabulin is a synthesized diketopiperazine derivatives,based on the structure-activity relationship(SAR)study of Phenylahistin which was isolated from Aspergillus.As an antitumor drug candidate,Plinabulin has been pushed into Phase III clinical study.In order to obtain high efficiency,low toxicity and higher bioavailability derivatives of Plinabulin,a number of derivatives have been designed and synthesized in recent years.In this review,the progress of the development of Plinabulin and its analogues was reported.
出处 《中国海洋药物》 CAS CSCD 2016年第4期79-86,共8页 Chinese Journal of Marine Drugs
基金 中国海洋大学"筑峰工程"人才计划项目(841412016)资助
关键词 普那布林(Plinabulin) 微管蛋白抑制剂 抗肿瘤候选药物 衍生物 构效关系 Plinabulin Tubulin inhibitor anti-tumor drug candidate derivative structure-activity relationship
  • 相关文献

参考文献31

  • 1Jordan M A, Wilson L. Microtubules as a target for antican- cer drugs[J]. Nat Rev Cancer, 2004, 4: 253-265.
  • 2李建农,蒋建东.微管的生物学特性与药物研究[J].药学学报,2003,38(4):311-315. 被引量:30
  • 3尚海,潘莉,杨澍,陈虹,程卯生.微管蛋白抑制剂的研究进展[J].药学学报,2010,45(9):1078-1088. 被引量:18
  • 4Dumontet C, Jordan M A. Microtubule-binding agents: a dynamic field of cancer therapeutics[J]. Nat Rev Drug Dis cov, 2010, 9:790-803.
  • 5Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy [ J]. Curr Med Chem-Anti-Cancer Agents, 2005, 5:65-71.
  • 6Pilat M J, LoRusso P M. Vascular Disrupting Agents[J]. J Cellular Biochem, 2006, 99:1021-1039.
  • 7Singh A V, Bandi M, Anderson K C, et al. A novel vascu- lar disrupting agent plinabulin triggers JNK-mediated apop- tosis and inhibits angiogenesis in multiple myeloma cells[J]. Blood,2011, 117(21) : 5692-5700.
  • 8Yamazaki Y, Kohno K, Hayashi Y, et al. Synthesis of bio- tin-tagged diketopiperazine-based anti-microtubule agents and tubulin photoaffinity labeling[J]. Springer Science Busi- ness Media, 2009: 527-528.
  • 9Kanoh K, Kohno S, Uno I, et al. ( )-Phenylahistin:a new mammalian cell cycle inhibitor produced by aspergillus ustus [J]. Bioorg Med Chem Lett, 1997, 7(22) : 2847-2852.
  • 10Kanoh K, Kohno S, Uno I, et al. Antitumor activity of phenylahistin in vitro and in vivo[J]. Biosei Biotechnol Bio- them, 1999, 63(6):1130-1133.

二级参考文献44

  • 1丁亚芳,包永明,安利佳.长春碱类抗肿瘤药物的研究进展[J].中国医药工业杂志,2005,36(7):424-428. 被引量:29
  • 2张宜平,徐飞,王旻.研究开发中的海洋抗癌活性物质[J].药学进展,2006,30(10):433-442. 被引量:1
  • 3肖亮,全海天,徐永平,唐卫东,富丽,楼丽广.长春氟宁抗肿瘤作用的研究[J].中国药理学通报,2007,23(4):507-511. 被引量:6
  • 4Nogales E, Wolf SG, Downing KH. Structure of the αβ tubulin dimmer by electron crystallography [J]. Nature, 1998,391(6663):199-203.
  • 5Dutcher SK. The tubulin fraternity: alpha to eta [J]. Curr Opin Cell Biol, 2001,13(1):49-54.
  • 6Menéndez M, Rivas G, Díaz JF, et al. Control of the structural stability of the tubulin dimer by one high affinity bound magnesium ion at nucleotide N-site [J]. J Biol Chem, 1998,273(1): 167-176.
  • 7Nogales E, Whittaker M, Milligan RA, et al. High-resolution model of the microtubule [J]. Cell, 1999,96(1):79-88.
  • 8Dumontet C, Sikic BL. Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death [J]. J Clin Oncol, 1999,17(3):1061-1070.
  • 9Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol [J]. Bri J Cancer, 1999,80(7):1020-1025.
  • 10Zheng YX, Wong ML, Alberts B, et al. Nucleation of microtubule assembly by a γ-tubulin-containing ring complex [J]. Nature, 1995,378(6557):578-583.

共引文献45

同被引文献9

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部